- Previous Close
91.91 - Open
91.62 - Bid 83.93 x 200
- Ask 99.26 x 200
- Day's Range
91.54 - 92.17 - 52 Week Range
82.15 - 98.95 - Volume
131,195 - Avg. Volume
304,627 - Market Cap (intraday)
3.011B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
70.05 - EPS (TTM)
1.31 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
96.86
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
www.amedisys.com19,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMED
View More
Performance Overview: AMED
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMED
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMED
View MoreValuation Measures
Market Cap
3.01B
Enterprise Value
3.17B
Trailing P/E
70.05
Forward P/E
19.92
PEG Ratio (5yr expected)
1.33
Price/Sales (ttm)
1.29
Price/Book (mrq)
2.65
Enterprise Value/Revenue
1.35
Enterprise Value/EBITDA
17.85
Financial Highlights
Profitability and Income Statement
Profit Margin
1.84%
Return on Assets (ttm)
6.24%
Return on Equity (ttm)
3.32%
Revenue (ttm)
2.35B
Net Income Avi to Common (ttm)
43.23M
Diluted EPS (ttm)
1.31
Balance Sheet and Cash Flow
Total Cash (mrq)
303.24M
Total Debt/Equity (mrq)
38.92%
Levered Free Cash Flow (ttm)
277.51M
Research Analysis: AMED
View MoreResearch Reports: AMED
View MoreWhat does Argus have to say about AMED?
AMEDISYS INC has an Investment Rating of HOLD; a target price of $96.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $96.00
AMEDISYS INC has an Investment Rating of HOLD; a target price of $96.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about AMED?
AMEDISYS INC has an Investment Rating of HOLD; a target price of $97.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about AMED?
AMEDISYS INC has an Investment Rating of HOLD; a target price of $97.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target